[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Basel, Switzerland\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":659},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,169,0,25,[9,53,90,118,154,181,205,223,246,265,293,313,333,354,389,414,436,454,483,511,536,559,586,622,640],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100054119","linezolid-plus-standard-of-care-100054119",false,"NCT06958835","Linezolid Plus Standard of Care","Combination Antibiotic Treatment With Linezolid for Staphylococcus Aureus Bacteraemia: a Randomised Controlled Trial","LIPS","Inclusion criteria:\n\n* Staphylococcus aureus (S. aureus) grown from at least one blood culture\n* Hospitalised at a participating centre\n* ≥18 years old\n* Written informed consent or fulfilling criteria for an emergency exception from informed consent requirements\n\nExclusion criteria:\n\n* Administration of the initial drug treatment not feasible within 72 hours since the collection of the first positive blood culture with S. aureus\n* Documented history of positive blood cultures for S. aureus occurring between 72 hours and 180 days prior to the eligibility assessment\n* Necrotising fasciitis\n* Currently receiving linezolid or clindamycin\n* Use of any monoamine oxidase A or B inhibitor within the last two weeks\n* Known hypersensitivity to linezolid or any other ingredients of the study drugs\n* Current severe thrombocytopenia (i.e. \\\u003C30 x 10\\^9\u002FL)\n* Application of study drug not possible (per mouth or per gastric tube)\n* Currently breastfeeding\n* Local treating team believes that death is imminent and inevitable\n* Patient is receiving end of life care and antibiotic treatment is not considered appropriate\n* Local treating team believes that participation in the study is not in the best interest of the patient\n* Any indication that the patient is unwilling to participate in the study including an advance directive stating such unwillingness","ALL","18 Years",{"count":21,"type":22},606,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.",[28],"Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)",[30,31,32,33,34,35,36,37,38,39],"Virulence factors","Linezolid","Bloodstream Infection","Hierarchical composite endpoint","Staphylococcus aureus","Bacteremia","Bacteraemia","Methicillin-resistant Staphylococcus aureus (MRSA)","Penicillin-susceptible Staphylococcus aureus (PSSA)","Methicillin-susceptible Staphylococcus aureus (MSSA)","RECRUITING","2026-07-09",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":44},"2025-10-06",{"date":48,"type":22},"2028-10",{"name":50,"class":51},"University Hospital, Basel, Switzerland","OTHER",12,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100644472","bridging-the-gap-in-psychosocial-care-for-cancer-survivors-100644472","NCT07672314","Bridging the Gap in Psychosocial Care for Cancer Survivors","Bridging the Gap in Psychosocial Care for Cancer Survivors: Integrating Digital Screening With Navigation Call","BRIDGE","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Under oncological care at the USB for ≥9 months\n* Completion of primary cancer treatment (see definition below)\n* Attendance at routine oncological follow-up at USB\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Primary brain tumors\n* Severe cognitive impairment\n* Acute psychiatric symptoms that may impair the participant's ability to provide informed consent or comply with study procedures\n* Insufficient German language skills",{"count":62,"type":22},50,[25],"The study aims to assess the feasibility and acceptability of the implementation of a routine digital psychosocial screening combined with a psycho-oncological Navigation Call for cancer survivors after completion of primary treatment with the goal to improve identification of psychosocial needs and facilitate access to supportive care.",[66,67,68,69],"Cancer Survivorship","Psychological Distress","Psycho-Oncology","Supportive Care",[71,72,73,74,75,76,77,78,79],"Cancer survivors","Survivorship care","Digital screening","Psycho-oncology","Psychosocial distress","Patient-reported outcomes (PROs)","Navigation Call","Feasibility study","Acceptability","NOT_YET_RECRUITING","2026-06-26",{"date":83,"type":44},"2026-06-29",{"date":85,"type":22},"2026-07",{"date":87,"type":22},"2028-05",{"name":50,"class":51},1,{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":18,"minAge":98,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},"100575574","swiss-prospective-cohort-of-transgender-and-gender-diverse-individuals---the-spectra-study-100575574","NCT06774053","Swiss ProspectivE Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study","Swiss Prospective Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study","SPECTRA","Inclusion Criteria:\n\n* Age 16 years and above.\n* Established diagnosis of gender incongruence\n* Indication for gender affirming therapy or ongoing or discontinued gender affirming therapy\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* Missing commitment or ability to study protocol adherence","16 Years",{"count":100,"type":22},600,"OBSERVATIONAL","The goal of this observational study is to understand the factors influencing the well-being and health of transgender and gender-diverse (TGD) individuals undergoing gender-affirming therapies in Switzerland. The study population includes TGD individuals aged 16 and older, at various stages of their medical transition, including those who have discontinued or detransitioned.\n\nThe main question is:\n\nWhat are the key factors influencing the well-being and health outcomes of transgender and gender-diverse individuals undergoing gender-affirming therapies?\n\nResearchers will compare health outcomes across different subgroups, such as those at different stages of transition or detransition, to examine the effects of gender-affirming therapies.\n\nParticipants will:\n\nComplete electronic questionnaires assessing gender congruence, quality of life, mental health, and other outcomes.\n\nProvide biological samples (e.g., blood, urine, stool, and skin swabs) for laboratory analysis.\n\nUndergo clinical evaluations related to endocrinology, fertility, dermatology, and urology as part of their routine follow-up.",[104,105],"Transgender Individuals","Gender Incongruence",[107,108,109],"Gender Affirming Hormone Therapy (GAHT)","Gender Affirming Surgery (GAS)","Transgender and Gender Diverse (TGD)",{"date":111,"type":44},"2026-06-30",{"date":113,"type":44},"2026-04-20",{"date":115,"type":22},"2046-01",{"name":50,"class":51},3,{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":18,"minAge":126,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100485045","impact-of-personalised-cardiac-anaesthesia-and-cerebral-autoregulation-on-neurological-outcomes-in-patients-undergoing-cardiac-surgery-100485045","NCT05595954","Impact of Personalised Cardiac Anaesthesia and Cerebral Autoregulation on Neurological Outcomes in Patients Undergoing Cardiac Surgery","Impact of Personalised Cardiac Anaesthesia and Cerebral Autoregulation on Neurological Outcomes in Patients Undergoing Cardiac Surgery (PRECISION)","PRECISION","Inclusion Criteria:\n\n* Elective primary or reoperative coronary artery bypass graft and\u002For valvular and\u002For ascending aorta surgery requiring cardiopulmonary bypass.\n\nExclusion Criteria:\n\n* Surgery requiring moderate (28-31.9ºC) or deep (\\\u003C28ºC) hypothermic circulatory arrest;\n* Heart and\u002For lung transplantation;\n* Urgent (within 24 hours) and emergency surgery;\n* Inability to follow procedures or insufficient knowledge in English, German or French;\n* Inability to give consent.\n\nParticipants who undergo cardiac surgery under minimal extracorporeal circulation will also be excluded.","65 Years",{"count":128,"type":22},500,"This international, multicentre prospective cohort study will assess whether perioperative duration and magnitude of mean arterial pressure (MAP) outside of an individual's cerebral autoregulation (CA) limits using near-infrared spectroscopy (NIRS) and transcranial Doppler (TCD) are associated with adverse neurological events. It is to investigate whether patients with a higher burden of cerebral haemodynamic insults have an increased incidence or poorer neurological outcomes. Associations between neurologic outcomes, neurobiomarkers and genetic tests will be explored.",[131,132,133],"Postoperative Delirium","Postoperative Stroke","Postoperative Cognitive Dysfunction",[135,136,137,138,139,140,141,142,143,144,145],"cerebral autoregulation","hypotension","neurological outcomes","adverse neurological events","postoperative delirium","postoperative stroke","postoperative cognitive decline","personalised cardiac anaesthesia","cardiac surgery","near-infrared spectroscopy","transcranial Doppler","2026-06-25",{"date":111,"type":44},{"date":149,"type":44},"2023-01-23",{"date":151,"type":22},"2027-06",{"name":50,"class":51},4,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":89},"100636759","copeptin-measurement-after-mannitol-and-hypertonic-saline-for-the-diagnosis-of-polyuria-polydipsia-syndrome-100636759","NCT07569861","Copeptin Measurement After Mannitol and Hypertonic Saline for the Diagnosis of Polyuria-polydipsia Syndrome","COMPASS","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Hypotonic polyuria\u002Fpolydipsia syndrome defined as polyuria \\>40ml\u002Fkg body weight\u002F24h and polydipsia \\>3l\u002F24h; and urine osmolality \\\u003C800mOsm\u002FL or known AVP-D based on accepted criteria\n\nExclusion Criteria:\n\n1. Polyuria\u002Fpolydipsia secondary to diabetes mellitus, hypercalcemia, or hypokalemia\n2. Diagnosis of AVP-R (Copeptin \\> 21.4 pmol\u002FL)\n3. Evidence of acute illness\n4. Epilepsy requiring treatment\n5. Uncontrolled arterial hypertension (blood pressure \\>160\u002F100mmHg at baseline\n6. eGFR \\\u003C 60 ml\u002Fmin\u002F1,73 m2\n7. Cardiac failure (NYHA III-IV)\n8. Diagnosis of liver cirrhosis, Child-Pugh Class C\n9. Uncorrected adrenal or thyroidal deficiency\n10. Pregnancy or breastfeeding\n11. Current or unresolved urinary obstruction\n12. Enrollment in a clinical trial within the last 30 days\n13. Patients refusing or unable to give written informed consent\n14. Inability to follow study procedures",{"count":162,"type":22},144,[25],"The aim of this study is to evaluate whether a new test using mannitol infusion can diagnose the cause of polyuria-polydipsia syndrome as accurately as the current standard test (hypertonic saline infusion) and to compare which test patients prefer. The goal is to identify a simpler and more patient-friendly diagnostic approach.",[166,167],"Arginine Vasopressin Deficiency","Primary Polydipsia",[169,170,171,172],"Copeptin Measurement","Diagnosis of Polyuria-polydipsia syndrome","Mannitol","Hypertonic Saline Infusion","2026-06-17",{"date":175,"type":44},"2026-06-18",{"date":177,"type":44},"2026-06-16",{"date":179,"type":22},"2030-06",{"name":50,"class":51},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":204},"100537603","pupillometric-evaluation-in-patients-declared-brain-dead---a-prospective-quality-control-study-100537603","NCT06279975","Pupillometric Evaluation in Patients Declared Brain Dead - a Prospective Quality Control Study","Investigative Neurological Study With Pupillometric Evaluation os a Clinical Tool in Patients Declared Brain Dead (INSPECT) - a Prospective Quality Control Study","INSPECT","Inclusion Criteria:\n\n* Suspected diagnosis of brain death\n* Brain death diagnostic procedures planned\n* Treated at the intensive care unit at the University Hospital Basel (USB)",{"count":62,"type":22},"The aim of the study is to verify the reliability of the current purely clinical examination of the pupils (without the support of a pupillometer) in the context of clinically suspected brain death, compared to the results of a non-invasive, automated, and highly precise monocular pupillometric examination.",[192,193],"Brain Death","Adults",[195,192,196],"Pupillometry","Diagnosis","2026-06-15",{"date":173,"type":44},{"date":200,"type":44},"2023-12-18",{"date":202,"type":22},"2030-12",{"name":50,"class":51},2,{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":222,"locationsCount":89},"100426171","firm-observational-clinical-unicenter-study-on-guillain-barr-syndrome-100426171","NCT04829526","Firm Observational Clinical Unicenter Study on Guillain Barré Syndrome","Firm Observational Clinical Unicenter Study on Guillain Barré Syndrome (FOCUS on GBS)","FOCUS on GBS","Inclusion Criteria:\n\n* suspected diagnosis of GBS, who have been treated at the University Hospital of Basel from 01.01.2005-28.02.2021\n\nExclusion Criteria:\n\n* Patients with documented refusal of the general consent.",{"count":214,"type":22},100,"The aim of this retrospective observational single-center cohort study is to gain a deeper understanding regarding the frequency, the clinical and electrophysiologic characteristics (e.g., the diagnostic work up), complications, treatment regimes, and their associations with specific courses of disease and outcomes in adult patients with the suspected or proven diagnosis of GBS.",[217],"Guillain-Barre Syndrome (GBS)",{"date":173,"type":44},{"date":220,"type":44},"2021-03-01",{"date":85,"type":22},{"name":50,"class":51},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":204},"100389241","advance-directive-implementation-and-scientific-evaluation-study-100389241","NCT04348318","Advance Directive Implementation and Scientific Evaluation Study","Advance Directive Implementation and Scientific Evaluation (ADVISE) Study","ADVISE","Inclusion Criteria:\n\n* adult patients treated for more than 48 hours in the intensive care unit (post-operative or internal medicine) of the University Hospital Basel in the years 2011-2023\n\nExclusion Criteria:\n\n* Patients with documented refusal of the general consent.\n* Patients who have been treated in the intensive care unit for less than 48 hours",{"count":232,"type":22},2000,"This study is to better understand the use of advance directives, their implementation in the intensive care unit, and their effects on outcome. Data from the digital medical records of all consecutive adult patients admitted to the intensive care unit at the University Hospital Basel from 2011 to 2023 are retrospectively extracted. Descriptive analyses will be applied to report the proportion of patients with an advance directive. In-hospital outcome (defined as survival, Glasgow Outcome Score, and return of neurologic function to premorbid baseline) will be compared between patients with and without advanced directives",[235],"Loss of Capability of Judgement",[237,238,239],"advance directives","life-sustaining treatment","neurocritical illness",{"date":173,"type":44},{"date":242,"type":44},"2021-08-03",{"date":244,"type":22},"2050-12",{"name":50,"class":51},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":264,"locationsCount":204},"100378231","status-epilepticus-population-study-steps-100378231","NCT04204863","Status Epilepticus Population Study (STEPS)","Inclusion Criteria:\n\n* Adult patients (i.e., patients ≥18 years of age) with diagnosed SE between 2005 and 2023 who have been treated at the University Hospital of Basel or the Cantonal Hospital Aarau.\n\nExclusion Criteria:\n\n* Patients younger than 18 years.\n* Patients with repetitive epileptic seizures not qualifying for SE.\n* Patients with documented refusal of the general consent.",{"count":253,"type":22},1000,"The aim of this observational multicenter cohort study is to gain a deeper understanding regarding the effects of treatment adaption based on information from outcome prediction models, risk stratification, as well as treatment monitoring, detection, prevention, and management of complications on course and outcome of adult patients with status epilepticus (SE).",[256],"Epileptic Seizures",[258,259],"Status epilepticus","Electroencephalogram",{"date":173,"type":44},{"date":262,"type":44},"2019-04-19",{"date":244,"type":22},{"name":50,"class":51},{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":126,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":292},"100528653","phase-2-treatment-of-patellofemoral-osteoarthritis-with-engineered-cartilage-100528653","NCT06163573","Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.","Treatment of Patellofemoral Osteoarthritis With Nasal Chondrocyte-based Engineered Cartilage Implantation in a Randomized, Controlled, Multi-center Phase II Clinical Trial","Inclusion Criteria:\n\n* Patient age is ≥18 and ≤ 65 years at time of screening.\n* Symptomatic PFOA grade 1-3 according to Iwano Classification\n* Chondropathy Grade 3-4 according to ICRS classification of the patella, trochlea femoris or both\n* Baseline score of \\\u003C60 on the KOOS Pain subjective knee evaluation.\n* Free range of motion of the affected knee joint or ≤ 5° of extension loss and minimum 125° flexion.\n* Patient is willing and able to give written informed consent to participate in the study and to comply with all study requirements, including attending all follow-up visits and assessments and to complete postoperative rehabilitation regimen.\n* Minimum values for women: Haemoglobin 120g\u002Fl, Platelets 150G\u002Fl, INR\\\u003C1.3\n* Minimum values for men: Haemoglobin 140g\u002Fl, Platelets 150G\u002Fl, INR\\\u003C1.3\n* Non-surgical standard of care options except for PRP have been exhausted.\n\nExclusion Criteria:\n\n* Patient is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol or in a dependency or employment with the sponsor.\n* Patient is unable to understand the patient information\n* Patient is unable to undergo magnetic resonance imaging (MRI)\n* Prior surgical treatment of the target knee within 12 months (Note: prior diagnostic arthroscopy with debridement and lavage are acceptable within 12 months).\n* Radiologically apparent degenerative joint disease of the tibiofemoral joint as determined by X-ray (Kellgren and Lawrence grade \\> 2) or MRI or pain in the tibiofemoral joint as assessed by clinical examination\n* Patient has excessive varus or valgus deformity (\\>5°)\n* Patient had a patellar dislocation in the afflicted knee in the last 2 years.\n* Patient has a symptomatic meniscus lesion (or removal exceeding ½), as indicated by clinical examination (joint line tenderness and McMurray test positive) and MRI.\n* Patient has a body mass index (BMI) \\>35 kg\u002Fm2.\n* Patient has chronic rheumatoid arthritis, and\u002For infectious arthritis\n* Any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee.\n* Patient has a known immunological suppressive disorder or is taking immunosuppressives.\n* Patient had any intra-articular injections into the affected knee within the last 3 months before baseline visit\n* Instability of anterior, posterior collateral ligaments\n* The patient has a HIV\u002FAIDS infection. (regulatory requirement)\n* The patient has an acute Treponema pallidum (syphilis) infection. (regulatory requirement)\n* The patient has an active hepatitis B or C infection with verified antigens. Patients with a cured hepatitis B or C infection and\u002For verified antibodies are not excluded. (regulatory requirement)\n* Patient is pregnant, breast feeding or anticipates becoming pregnant within 24 months after surgery.\n* Patient is currently participating or has participated in any other clinical study within 3 months prior to the screening visit.\n* Patient has known current or recent history of illicit drug or alcohol abuse or dependence defined as the continued use of alcohol or drugs despite the development of social, legal or health problems.\n* Patient has any other condition, which, in the opinion of the investigator, would make the patient unsuitable for the study.\n* Any known allergies, especially for porcine collagen, penicillin or streptomycin (manufacturing)\n* patients with increased anesthesiological and surgical risks (e.g. known or predicted difficult airway, myocardial infarction \\\u003C60 days prior to surgery)\n* patients with increased bleeding risk (e.g. coagulopathies)\n* patients on anticoagulants whose anticoagulant therapy cannot be interrupted as appropriate to the given agent(s) and underlying condition\n* Patients with any active infections",{"count":273,"type":22},75,[275],"PHASE2","The purpose of this investigator-initiated study is to assess the efficacy of treating patellofemoral osteoarthritis with an Advanced Therapy Medicinal Product (ATMP), autologous nasal chondrocyte tissue engineered cartilage (N-TEC), in comparison with a standard therapy using platelet rich plasma injections.\n\nThe engineered cartilage graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen type I\u002FIII membrane.",[278],"Patellofemoral Osteoarthritis",[280,281,282,283],"Nasal chondrocytes","Tissue engineering","Knee cartilage","Patellofemoral osteoarthritis","2026-06-10",{"date":286,"type":44},"2026-06-11",{"date":288,"type":44},"2024-06-06",{"date":290,"type":22},"2029-09",{"name":50,"class":51},9,{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":89},"100429797","wheat-beer-for-prevention-of-delirium-in-intensive-care-patients-100429797","NCT04876742","Wheat Beer for Prevention of Delirium in Intensive Care Patients","A Randomised Placebo-controlled Double-blind Exploratory Trial Within Cohort Using Wheat Beer for Prevention of Delirium in Intensive Care Patients","BABE-D","Inclusion criteria\n\nAll Patients meeting the following criteria are eligible for the study:\n\n* Risk of delirium: ICU patients with expected length of stay (LOS) ≥ 24 hours\n* Naso-gastric tube in situ\n* ICU stay ≤ 72h until first study intervention\n* Women: negative pregnancy test, age ≥50 years or status post hysterectomy\u002Fbilateral ovariectomy\n* Adult patients (age ≥ 18 years)\n* ≥ 50 kg body weight or BMI ≥18.5\n\nExclusion Criteria\n\nPatients fulfilling the following criteria are excluded from the study:\n\n* Pre-existing liver pathologies\n* Patients after bone marrow transplantation\n* Women: breastfeeding\n* Pre-existing delirium (ICDSC ≥ 4)\n* Terminal state\n* Active psychosis\n* Anamnestic complete alcohol abstinence or status post alcohol abuse\n* Especially vulnerable patients\n* Allergy to any ingredient(s) of beer",{"count":302,"type":22},380,[25],"The investigators hypothesise that the daily administration of 0.5L alcohol-containing wheat beer at 8 pm over a study period of 6 days in a row leads to a lower prevalence of delirium compared to water following the same administration scheme.",[306],"ICU Delirium",{"date":286,"type":44},{"date":309,"type":44},"2023-01-18",{"date":311,"type":22},"2029-12-31",{"name":50,"class":51},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":89},"100405162","phase-4-enhancement-of-the-haemostatic-effect-of-platelets-in-the-presence-of-high-normal-concentrations-of-von-willebrand-factor-100405162","NCT04555785","Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor","Will-Plate","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Admission to intensive care unit\n* Patients needing platelet transfusion during or after surgery with or without prior treatment with single or dual antiplatelet agents (ASS, Prasugrel, Clopidogrel, Ticagrelor)\n* Consent by the patient or a family member in addition to the consent of an independent ICU physician\n\nExclusion Criteria:\n\n* Patients receiving Factor VIII concentrate before inclusion of the study (Haemate ®)\n* Women who are pregnant or breastfeeding\n* Participation in another study with an investigational drug within the 30 days preceding and during the present study\n* Overt Disseminated Intravascular Coagulation (DIC)\n* Heparin-induced Thrombocytopenia (HIT)\n* Thrombotic Thrombocytopenic Purpura (TTP) or Haemolytic uremic Syndrome (HUS)\n* Idiopathic thrombocytopenic purpura (ITP)\n* Sepsis\n* Patients with known inherited thrombocytopathies\n* Patients with known von Willebrand disease or Haemophilia A\n* Patients with known hemato-oncological diseases\n* Previous enrolment into the current study\n* Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product.",{"count":321,"type":22},120,[323],"PHASE4","Assessment of high-normal dosage of Wilate ® compared to placebo administered in combination with platelets to assess reduction of amount of blood loss, need of transfusion products and outcome (length of stay, mortality) in patients with bleeding in comparison.",[326],"Bleeding",{"date":286,"type":44},{"date":329,"type":44},"2022-04-01",{"date":331,"type":22},"2028-11",{"name":50,"class":51},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":18,"minAge":341,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":23,"phases":344,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":89},"100319420","phase-4-the-basel-bomp-aid-randomized-trial-100319420","NCT03438526","The Basel BOMP-AID Randomized Trial","Better Outcome With Melatonin Compared to Placebo Administered to Normalize Sleep-wake Cycle and Treat Hypoactive ICU Delirium The Basel BOMP-AID Randomized Trial","BOMP-AID","Inclusion Criteria:\n\nParticipants fulfilling all of the following inclusion criteria are eligible for the study:\n\n* Adult patients (aged 55 years or older)\n* Current delirium (hypoactive type) detected by a specialised assessment method: ICDSC score \\>2 and RASS score \\\u003C 0\n\nExclusion Criteria:\n\nParticipants meeting the following criteria are excluded from the study:\n\n* Delirium prior to ICU admission\n* Sleep disorder not caused by hypoactive delirium\n* Sedation in the ICU\n* Hypersensitivity to the studied substances (i.e., melatonin, placebo content)\n* Age \\\u003C55 years\n* Terminal state\n* Status epilepticus or postictal states following seizures on electroencephalogram (EEG)\n* Active psychosis\n* Substance abuse in current medical history\n* Dementia\n* Pregnancy","55 Years",{"count":343,"type":22},190,[323],"Delirium is a neurobehavioural syndrome that frequently develops in the postoperative and\u002For ICU setting. The incidence of elderly patients who develop delirium during hospital stay ranges from 11-82%. Delirium was first described more than half a century ago in the cardiac surgery population, where it was already discovered as a state that might be accompanied by serious complications such as prolonged ICU and hospital stay, reduced quality of life and increased mortality. Furthermore, the duration of delirium is associated with worse long-term cognitive function in the general ICU population. This long-term experience with delirium suggests a high socioeconomic liability and has been a focus of many studies. The aforementioned consequences of delirium are observed in all of three subtypes: hypoactive, hyperactive, and mixed. Pharmacological treatment options for hypoactive delirium are lacking. Since patients in hypoactive delirium suffer from disturbed circadian rhythm, the investigators suggest that the administration of melatonin as a promising possibility in these patients to shorten delirium duration and to lower its severity. Previous investigations confirmed loss of melatonin rhythm in patients that had developed delirium thus reasoning the study hypothesis.\n\nIn this randomized study, the investigators aim to test the hypothesis that the reinstitution of a normal circadian rhythm by the administration of melatonin compared to placebo after diagnosis of hypoactive delirium, decreases the duration of delirium and reduces the transmission to a form of agitated delirium. The administration might have to be repeated several times to achieve resolution of delirium.",[347],"Hypoactive Delirium",{"date":286,"type":44},{"date":350,"type":44},"2022-01-03",{"date":352,"type":22},"2027-12",{"name":50,"class":51},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":362,"targetDuration":364,"studyType":101,"phases":4,"briefSummary":365,"conditions":366,"keywords":374,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":89},"100643069","beat-shock-registry-100643069","NCT07643610","BEAT-SHOCK Registry","BEAT-SHOCK (Basel Evaluation of Acute Therapy in Cardiogenic SHOCK) Registry","BEAT-SHOCK","* Patients admitted with cardiogenic shock to the University hospital Basel (diagnosis at the time of admission) or development of cardiogenic shock during the hospital stay\n* Age ≥18 years\n* Provision of written ICF\n* Clinical diagnosis of cardiogenic shock.\n* impaired organ perfusion due to primary cardiac dysfunction,\n* persistent systolic blood pressure (SBP) \\\u003C90 mmHg for ≥30 minutes, or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain adequate perfusion and\n* evidence of systemic hypoperfusion with arterial lactate ≥2 mmol\u002FL or venous lactate ≥3 mmol\u002Fl and ≥1 of the following:\n* Cold or clammy extremities\n* Altered mental status\n* Reduced urine output\n* Signs of volume overload or congestion (on clinical exam, imaging, or invasive monitoring)\n* Patients with normotensive cardiogenic shock (SBP ≥90 mmHg without vasopressors or MCS) may also be included if clear signs of hypoperfusion (arterial lactate ≥2 mmol\u002FL or venous lactate ≥3 mmol\u002Fl) and cardiac dysfunction are present and alternative causes are excluded\n\nExclusion criteria:\n\n* Age \\\u003C18 years\n* Refusal to provide informed consent by the patient or their legally authorized representative",{"count":363,"type":22},8000,"5 Years","This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.",[367,368,369,370,371,372,373],"Cardiogenic Shock","Myocardial Infarction (MI)","Fulminant Myocarditis","Acute Decompensated Heart Failure","Severe Valvular Disease","Post-cardiotomy","Perioperative Cardiogenic Shock",[375,376,377,378,379,380,381],"cardiogenic shock","Myocardial infarction (MI)","Fulminant myocarditis","Acute decompensated heart failure","Severe valvular disease","Post-cardiotomy or perioperative cardiogenic shock","wide range of cardiogenic shock etiologies","2026-06-08",{"date":286,"type":44},{"date":385,"type":44},"2025-10-01",{"date":387,"type":22},"2035-10-01",{"name":50,"class":51},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":397,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":23,"phases":400,"briefSummary":401,"conditions":402,"keywords":404,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":4},"100376862","simplify-the-hand-hygiene-procedure---three-steps-versus-six-steps-for-performing-hand-hygiene-simplify-study-100376862","NCT04187040","SIMPLIFY the Hand Hygiene Procedure - Three Steps Versus Six Steps for Performing Hand Hygiene (SIMPLIFY Study)","SIMPLIFY the Hand Hygiene Procedure - Three Steps Versus Six Steps for Performing Hand Hygiene - an International Multicenter Cluster Randomized Trial (SIMPLIFY Study)","SIMPLIFY","Inclusion Criteria:\n\nHealth Care Workers (HCW) working at the randomized wards during the pre-defined timeframe\n\nExclusion Criteria:\n\nIndividuals, who are no HCWs",true,{"count":399,"type":22},40,[25],"Hand hygiene is one of the most important measures to prevent healthcare associated infections. A hand hygiene technique consisting of three steps may be superior to the 6-step technique outlined by the World Health Organization (WHO) in terms of compliance with both indications and technique. Therefore, the aim of this study is to compare compliance with hand hygiene indications and technique between a 3-step and the 6-step technique for applying hand rub in an international multicenter cluster randomized trial.",[403],"Hand Hygiene",[405,406,407],"WHO-guideline on hand hygiene in healthcare","3-step hand hygiene technique","6-step hand hygiene technique","2026-06-04",{"date":382,"type":44},{"date":411,"type":22},"2026-12",{"date":411,"type":22},{"name":50,"class":51},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":422,"conditions":423,"keywords":425,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":89},"100370037","epidemiology-of-carbapenemase-producing-bacteria-in-a-swiss-tertiary-care-hospital-100370037","NCT04098133","Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital","CPB-Epi Basel","Inclusion Criteria:\n\n* Patients with detection of carbapenemase-producing bacteria from January 1st , 2008 until December 31st , 2028\n\nExclusion Criteria:\n\n* Patients with documented refusal of subsequent use of their data",{"count":214,"type":22},"This retrospective and prospective study is to investigate the incidence of Carbapenemase-producing bacteria (CPB) at the University Hospital Basel, the time to detection of CPB and to initiation of infection control measures, the risk factors associated with carriage of CPB, type and duration of previously administrated antibiotic medication, antibiotic treatment, as well as to assess the outcomes of the affected patients.",[424],"Infections With CPB",[426,427,428,429],"Carbapenemase-producing Klebsiella pneumoniae","antibiotic resistancy","infections with Carbapenemase-producing Bacteria (CPB)","Carbapenemase-producing Bacteria",{"date":382,"type":44},{"date":432,"type":44},"2019-08-22",{"date":434,"type":22},"2029-06-30",{"name":50,"class":51},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":18,"minAge":443,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":89},"100321501","transmission-of-esbl-producing-enterobacteriaceae-100321501","NCT03465683","Transmission of ESBL-producing Enterobacteriaceae","Transmission of ESBL-producing Enterobacteriaceae and Their Mobile Genetic Elements-identification of Sources by Whole Genome Sequencing","Inclusion Criteria:\n\n* aged above 1 year\n* proven ESBL-PE carriage from any specimens obtained by routine clinical practice out and inpatients from University Hospital Basle from January 1st until December 31st 2019\n\nExclusion Criteria:\n\n* not meeting inclusion criteria","1 Year",{"count":232,"type":22},"The aim of this research project is to investigate the transmission of ESBL-producing Enterobacteriaceae on both, the level of bacterial strains and mobile genetic elements, and to determine the source of hospital-acquired infections.",[447],"Hospital Acquired Infection",{"date":382,"type":44},{"date":450,"type":44},"2017-03-01",{"date":452,"type":22},"2026-12-31",{"name":50,"class":51},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":23,"phases":464,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":482},"100507691","the-lymph-trial---microsurgical-versus-conservative-treatment-of-chronic-breast-cancer-associated-lymphedema-100507691","NCT05890677","The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema","The LYMPH Trial - Comparing Microsurgical With Conservative Treatment of Chronic Breast Cancer Associated Lymphedema: Study Protocol of a Pragmatic Randomized International Multicentre Superiority Trial","LYMPH","Inclusion Criteria:\n\n* Written informed consent.\n* Patients ≥ 18 years of age.\n* Former diagnosis of breast cancer.\n* Clinical diagnosis of chronic Breast Cancer-Related Lymphedema (BCRL) (persisting for more than 3 months) classified as ≥ Stage 1, according to ISL.\n* Minimum of 3 months Conservative Complex Physical Decongestion Therapy.\n* Ability to complete the QoL questionnaires.\n* Willingness to undergo surgery.\n\nExclusion Criteria:\n\n* No indication for lymphatic surgery according to clinical judgment of the treating surgeon (individual reasons will be specifically documented).\n* Primary congenital Lymphedema or non-BCRL.\n* Previous surgical BCRL treatment on the side intended for intervention.",{"count":463,"type":22},280,[25],"The aim of this study is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema)) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema (LE)",[467],"Lymphedema, Breast Cancer",[469,470,471,472,473,474],"lymphatic surgery","breast cancer related lymphedema","sentinel lymph node biopsy","axillary lymph node dissection","manual lymphatic drainage","conservative complex physical decongestion therapy","2026-06-03",{"date":408,"type":44},{"date":478,"type":44},"2023-07-14",{"date":480,"type":22},"2036-06",{"name":50,"class":51},36,{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":498,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":509,"locationsCount":510},"100576776","reduce-tobacco-use-in-people-living-with-hiv-in-switzerland-100576776","NCT06789692","Reduce Tobacco Use in People Living With HIV in Switzerland","Reduce Tobacco Use in People Living With HIV in Switzerland: A Pragmatic Randomized Trial Within the Swiss HIV Cohort Study","RETUNE","Inclusion Criteria:\n\n* Signed informed consent for the data collection and participation in the SHCS (Cohort consent).\n* Signed informed consent to be randomized to future interventions (Randomization consent).\n* Age 18 years or older.\n* Smoked one or more tobacco cigarettes per day (smoking status = yes) at the time of enrolment.\n\nExclusion Criteria:\n\n* Currently using e-cigarettes or nicotine pouches or nicotine patches.\n* Pregnant women.",{"count":492,"type":22},972,[25],"The purpose of this trial is to test the effectiveness of offering a menu of different tobacco smoking substitutional products (e-cigarettes, nicotine pouches, nicotine patches in addition to usual of care) for smokers in the SHCS (Swiss HIV Cohort Study) in achieving self-reported 7-day tobacco cigarette abstinence at 6 months.",[496,497],"HIV","Smoking",[499,500,501,502],"tobacco smoking","e-cigarettes","tobacco-free nicotine pouches","Trials within Cohorts (TwiCs)","2026-05-28",{"date":505,"type":44},"2026-06-02",{"date":507,"type":44},"2025-02-20",{"date":352,"type":22},{"name":50,"class":51},7,{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":397,"sex":18,"minAge":19,"maxAge":519,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":522,"briefSummary":523,"conditions":524,"keywords":527,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":534,"leadSponsor":535,"locationsCount":89},"100624391","sensory-stimulation-as-a-driver-of-diet-induced-thermogenesis-100624391","NCT07409025","Sensory Stimulation as a Driver of Diet-induced Thermogenesis","SEnsory stimulatioN aS A Driver of dieT-induced Thermogenesis - the SENSATION Trial","SENSATION","Inclusion Criteria:\n\n* healthy volunteers of any gender\n* BMI between 18-25 kg\u002Fm2\n* age between 18 and 40 years\n\nExclusion Criteria:\n\n* concomitant medication except for prescription free analgetics (paracetamol, NSAIDs) and oral contraceptives\n* clinically significant concomitant disease states (e.g. renal failure, hepatic dysfunction, cardiovascular disease, diabetes mellitus),\n* allergy to local anaesthetic or any of the study meal ingredients\n* known or suspected non-compliance, drug or alcohol abuse\n* smoker \u002F habitual tobacco use\n* habitual excessive alcohol consumption\n* inability to follow the procedures of the study\n* participation in another study with investigational drug within the 30 days preceding and during the present study\n* previous enrolment into the current study\n* enrolment of the investigator, his\u002Fher family members, employees and other dependent persons\n* uncontrolled hypo- or hyperthyroidism\n* pregnancy or lactation","40 Years",{"count":521,"type":22},24,[25],"This study aims to assess the influence of sensory stimulation on diet-induced energy expenditure by way of a clinical cross-over trial in 24 healthy participants either receiving a meal bolus with (orally) and without sensory stimulation (nasogastric-tube).",[525,526],"Diet-induced Thermogenesis","Sensory Function",[528,529],"Diet-induced thermogenesis","Sensory Stimulation","2026-05-21",{"date":532,"type":44},"2026-05-22",{"date":197,"type":22},{"date":151,"type":22},{"name":50,"class":51},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":543,"minAge":19,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":546,"conditions":547,"keywords":550,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":557,"leadSponsor":558,"locationsCount":89},"100623549","pilot-observational-study-of-an-integrative-cure-stay-program-100623549","NCT07398079","Pilot Observational Study of an Integrative Cure Stay Program","Via Shalva","Inclusion Criteria:\n\n* Breast and gynecological cancer (including but not limited to ovarian, endometrial, cervical, vulvar and vaginal cancer) survivors, including recurrent disease\n* Completed primary treatment (operation +\u002F- radiation +\u002F- chemotherapy)\n* Age ≥ 18 years\n* Ongoing or planned maintenance treatment scheduled for \\> 3 months during study period is allowed (e.g. antihormonal therapy, Anti-Her2-antibodies, CDK4\u002F6-inhibitors, Anti-VEGF-inhibitor, PARP-inhibitor, immune-checkpoint inhibitors etc.)\n* Signed informed consent for participation of the trials\n* Presence of a stoma is allowed\n* Prior cancer is allowed\n* Prior treatment - including chemotherapy - for a prior malignant tumor (including breast or gynecological cancer) is allowed\n* Concomitant participation in an experimental therapeutic drug trial is allowed\n* Use of other complementary methods (including mistletoe) is allowed\n* Pregnancy is allowed.\n\nExclusion Criteria:\n\n* Language or cognitive deficits (including impaired consciousness) that are incompatible with the participation in the study\n* Severe physical or psychiatric comorbidity that prevents a patient from participating in the study\n* Patients incapable of giving consent","FEMALE",{"count":545,"type":22},30,"This pilot observational study evaluates the feasibility and acceptability of conducting a prospective study alongside the individualized integrative oncology cure stay program \"Via Shalva\" for breast and gynecological cancer survivors. The study further explores preliminary changes in patient-reported outcomes, physiological measures, and biological markers before and after the retreat and compared with a matched control group.",[548,549],"Breast Cancer","Gynecologic Cancer",[551,552,553],"Complementary Therapies","Integrative Medicine","Feasibility Studies","2026-05-19",{"date":532,"type":44},{"date":46,"type":44},{"date":151,"type":22},{"name":50,"class":51},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":585,"locationsCount":89},"100634977","role-of-axillary-lymph-node-dissection-for-residual-macrometastases-after-neoadjuvant-chemotherapy-in-patients-with-her2-and-triple-negative-breast-cancer-the-opbc-11macronac-study-100634977","NCT07546695","Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11\u002FMACRONAC Study","MACRONAC","Inclusion Criteria:\n\n* Women and men with a diagnosis of stage I-III TNBC or HER2+ breast cancer at diagnosis. HER2+ is defined as an Immunohistochemistry (IHC) score of 3+ or positive FISH. TNBC is defined as ER and Progesterone Receptor (PR) IHC expression of 0 and HER2 negativity defined as either IHC expression of 0-1+ or lack of gene amplification (FISH \\\u003C 2.0). Patients with ER low (1-10%) and\u002For PR low (1-10%) tumors are allowed.\n* Any histological subtype\n* For Clinical Nodal Stage (cN) 0 at presentation: any axillary staging technique including palpation with or without imaging is allowed. Dual tracer mapping is not required for SLN surgery.\n* For cN+ at presentation: Percutaneous biopsy proven confirmation is required at diagnosis. Staging techniques after NAC include: SLN surgery with dual mapping or Targeted Axillary Dissection (TAD: imaging-guided localization of sampled node in combination with SLN procedure with or without dual mapping) or Tailored Axillary Surgery (TAS: removal of the sentinel lymph nodes as well as selective removal of all palpable disease and documentation of the removal of the initially biopsy-proven and clipped lymph node metastasis by specimen radiography) or the MARI procedure (Marking Axillary Lymph Nodes with Iodine Seeds).\n* Received neoadjuvant chemotherapy\n* Residual macrometastases (metastasis greater than 2 mm in diameter) detected on SLN surgery or TAD ot TAS or MARI (on frozen section or final pathology)\n* Concomitant presence of Isolated Tumor Cells (ITCs) and micrometastases in other sentinel lymph nodes is allowed\n* Following SLN surgery\u002FTAD\u002FTAS\u002FMARI patients underwent completion ALND, nodal radiation therapy (RT), both or no further axillary treatment\n* At least 1-year follow-up (had surgery at any time point until October 2024 at the latest) - Prior history of ductal carcinoma in situ (DCIS) is allowed\n\nExclusion Criteria:\n\n* Did not undergo SLN surgery\u002FTAD\u002FTAS\u002FMARI (e.g., went straight to ALND)\n* Presence of ITCs or micrometastases alone in the sentinel nodes (or TAD nodes or MARI node or TAS nodes) without macrometastases\n* HR+HER2- tumors (except ER low and or PR-low)\n* Stage IV disease at presentation\n* Inflammatory breast cancer at presentation\n* Neoadjuvant endocrine therapy\n* Macrometastases detected by Oncoplastic Breast Consortium (OSNA)",{"count":100,"type":22},"In this multicenter retrospective cohort study the aim is to determine the safety of omission of axillary lymph node dissection in patients with TNBC and HER2+ tumors with residual macrometastases (in the SLN\u002FTAD\u002FTAS or MARI node) after NAC.",[548],[570,571,572,573,574,575,576,577,578,579],"Axillary lymph node dissection (ALND)","Triple Negative Breast Cancer (TNBC)","Breast Conserving Surgery (BCS)","Human Epidermal Growth Factor Receptor 2 Positive\u002F Negative (HER2+\u002F- )","Hormone Receptor Positive\u002F Negative (HR+\u002F-)","Neoadjuvant Chemotherapy (NAC)","Targeted Axillary Dissection (TAD)","Tailored Axillary Surgery (TAS)","Marking Axillary Lymph Nodes with Iodine Seeds (MARI)","Sentinel Lymph Node (SLN)","2026-05-18",{"date":554,"type":44},{"date":583,"type":44},"2026-02-01",{"date":352,"type":22},{"name":50,"class":51},{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":397,"sex":18,"minAge":594,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":23,"phases":596,"briefSummary":597,"conditions":598,"keywords":600,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":617,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":621,"locationsCount":204},"100637091","combacal-hiv-prevention-twics-100637091","NCT07581600","ComBaCaL HIV Prevention TwiCs","Community-based, Village Health Worker-led, eHealth-supported, Integrated HIV Prevention for People at Substantial Risk of HIV Acquisition in Rural Lesotho: Protocol for a Cluster-randomized Hybrid Type 1 effectiveness-implementation Trial Within the ComBaCaL Cohort Study","CoPrev","Inclusion Criteria:\n\n* Participant of the ComBaCaL cohort study (signed informed consent available)\n* Weight ≥ 35 kg\n* Negative HIV screening test\n* No potential exposure to HIV more than 72 hours ago (PEP eligibility window period) and less than 4 weeks ago (window period HIV test)\n* At substantial risk of HIV acquisition as per behavioural risk factors in the Lesotho's national HIV prevention and treatment guidelines:\n\n  * Report of serodiscordant partner who are not virally suppressed or have an unknown viral suppression status (either not on ART, initiated ART within the last 6 months, known virally unsuppressed or unknown virally suppression status but believed not to be taking treatment regularly)\n  * Report of sexual partner with unknown HIV status\n  * Report of unprotected sex with more than one partner in the last 6 months\n  * Report of STI by lab-testing or self-report of STI syndromic management in the last 6 months\n  * Report of exchanging money\u002Fgoods for sex in the last 6 months (as recipient and vice versa)\n  * Report of intravenous drug use with shared equipment in the last 6 months\n  * Request for biomedical HIV prevention\n\nExclusion Criteria:\n\n* Known allergies to PEP\u002Foral PrEP\n* Known glomerular filtration rate (GFR) \\\u003C 60 ml\u002Fmin or diagnosis of moderate\u002Fsevere kidney disease or kidney failure","15 Years",{"count":302,"type":22},[25],"This cluster-randomized intervention is embedded in the ComBaCaL (Community-Based Chronic disease care Lesotho) cohort study (EKNZ ID AO\\_2022-00058, clinicaltrials.gov ID NCT05596773, Lesotho NH-REC ID 210-2022), a platform for the investigation of chronic diseases and their management in rural Lesotho that is maintained by local lay chronic care village health workers (CC-VHWs).\n\nThis study is to evaluate the effectiveness and safety of the CoPrev model in regard to biomedical HIV prevention utilization compared with an enhanced standard of care, in which VHWs assisted by a tablet-based CDS application, perform the same activities except for the prescription and\u002For delivery of PEP, oral PrEP, COC and self-injectable contraception. Additionally, this study aims to assess the outcomes and processes related to the implementation of such a model.",[599],"Human Immunodeficiency Virus (HIV)",[601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,502],"Community-Based Chronic Disease Care Lesotho (ComBaCaL) cohort study","Low- and middle-income countries (LMICs)","Clinical decision support (CDS)","Community health worker (CHW)","Adolescent girls and young women (AGYW)","Pre-Exposure Prophylaxis (PrEP)","Post-Exposure Prophylaxis (PEP)","Village health worker (VHW)","Tenofovir Disoproxil Fumarate (TDF)","Lamivudine (3TC)","Dolutegravir (DTG)","Combined oral contraception (COC)","Antiretroviral therapy (ART)","Sexually transmitted infection (STI)","Levonorgestrel (LNG)","Ethinylestradiol (EE)",{"date":532,"type":44},{"date":619,"type":22},"2026-06",{"date":151,"type":22},{"name":50,"class":51},{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":627,"acronym":4,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":629,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":631,"conditions":632,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":89},"100362114","bowel-functionqol-after-elective-sigmoidectomy-vs-conservative-management-for-recurrent-uncomplicated-diverticulitis-100362114","NCT03994978","Bowel Function\u002FQoL After Elective Sigmoidectomy vs. Conservative Management for Recurrent Uncomplicated Diverticulitis","Preoperative vs. Postoperative Bowel Function and Quality of Life in Patients Undergoing Elective Sigmoidectomy vs. Conservative Management for Recurrent Uncomplicated Diverticulitis (FRESCO-Trial)","Inclusion Criteria:\n\n* Patients with recurrent uncomplicated diverticulitis and surgical indication for sigmoid resection\n* Patients with recurrent uncomplicated diverticulitis and non-surgical indication for conservative management\n* Confirmation of at least one episode of acute uncomplicated diverticulitis in computed tomography\n\nExclusion Criteria:\n\n* Patients aged under 18.\n* Patients unable to understand an informed consent.\n* Patients with chronic pain disorder.\n* Patients with sigmoid fistulas\n* Emergency operations.\n* Pregnant women or lactation.\n* Patients with other severe gastrointestinal diseases, such as inflammatory bowel diseases (IBD), carcinoma or immunologic disorders.\n* Patients unable to perform surgery or high-risk patients according to the American Society of Anesthesiology (ASA 4 grade or higher)",{"count":630,"type":22},252,"The decision to perform a surgical intervention or not after recovery from repeated uncomplicated episodes of acute diverticulitis remains controversial and the literature shows different conflicting approaches based on low-quality evidence.The goal of this trial is to achieve a better understanding of the impact of surgery on bowel function and QoL in patients with recurrent uncomplicated sigmoid diverticulitis in order to develop treatment guidelines.",[633],"Diverticulitis of Sigmoid",{"date":532,"type":44},{"date":636,"type":44},"2019-07-08",{"date":638,"type":22},"2028-12-31",{"name":50,"class":51},{"id":641,"slug":642,"hasResults":12,"nctId":643,"briefTitle":644,"officialTitle":644,"acronym":4,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":646,"targetDuration":648,"studyType":101,"phases":4,"briefSummary":649,"conditions":650,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":204},"100641189","t1g3r-1-trial-detectability-and-prognostic-value-of-ctdna-in-t1-g3-bladder-cancer-100641189","NCT07581496","T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer","Inclusion Criteria:\n\n* patients \\> 18 years of age, able to give informed consent as documented by signature,\n* patients with a cystoscopically proven bladder cancer, suspicious for T1 stage, who will undergo TUR-B\n\nExclusion Criteria:\n\n* Patients with metastases or concomitant upper tract tumor at diagnosis will\n* Patients with non T1 G3 cancers\n* Patients with upstaging, either at re-TUR-B or after immediate radical cystectomy\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.\n* Vulnerable persons (e.g. \\\u003C 18y of age, unable to consent to the study)",{"count":647,"type":22},35,"3 Years","T1G3 bladder cancer is a heterogeneous disease with a high risk of disease persistence after the first TUR-B, understaging, disease progression, bladder removal, and mortality.\n\nCurrent risk stratification is insufficient and needs improvement. Ct-DNA could identify patients with disease persistence, progression and could monitor and tailor therapy. It might improve patient risk stratification, avoiding under- and overtreatment, reducing morbidity and mortality.\n\nPrimary objective is to investigate the detectability of ct-DNA in T1G3 urothelial bladder cancer patients and build a biobank through collection of different sample types (urine, plasma) in T1G3 bladder cancer patients which allows future retrospective testing.",[651],"Bladder Cancer","2026-05-14",{"date":580,"type":44},{"date":655,"type":44},"2025-06-18",{"date":657,"type":22},"2030-06-01",{"name":50,"class":51},""]